Over 60 companies across the globe claim to manufacture drug products / drug substances ::

The COVID-19 pandemic has severely impaired the overall pharmaceutical supply chain, mostly owing to the absence of workers at manufacturing sites and restrictions imposed on distribution networks. In this context, continuous manufacturing offers a viable solution given the fact that continuous processes are largely automated. In fact, the FDA (and other regulatory bodies) have also expressed interest in advocating a shift to the use of advanced manufacturing technologies, such as continuous manufacturing.
To order this 310+ page report, which features 110+ figures and 200+ tables, please visit this link
The USD 1.9 billion (by 2030) financial opportunity within the continuous manufacturing market has been analyzed across the following segments:
Purpose of Manufacturing
  • In-House
  • Contract service
Scale of Operation
  • Commercial
  • Preclinical / Clinical
Type of Continuous Manufacturing related Service
API Manufacturing
End Product manufacturing
Type of Drug Molecule
  • Biologic
  • Small Molecule
Type of dosage form
  • Solid
  • Liquid
Key Geographical Regions
North America
Asia Pacific
The Continuous Manufacturing Market (Small Molecules and Biologics), 2020 – 2030 report features the following companies, which we identified to be key players in this domain: 
  • AbbVie Contract Manufacturing
  • Ajinomoto Bio-Pharma Services
  • Almac
  • Boehringer Ingelheim BioXcellence
  • Cambrex
  • CordonPharma
  • Hovione
  • Kaneka
  • Lonza
  • Patheon
  • SK biotek
Table of Contents
1. Preface

2. Executive Summary

3. Introduction

4. Market Landscape

5. Companies with Expertise in Continuous Manufacturing in North America: Profiles

6. Companies with Expertise in Continuous Manufacturing in Europe: Profiles

7. Companies with Expertise in Continuous Manufacturing in Asia-Pacific: Profiles

8. Recent Partnerships and Collaborations

9. Recent Expansions

10. Capacity Analysis

11. Academic Grant Analysis

12. Patent Analysis

13. Initiatives of Companies with In-House Continuous Manufacturing Capabilities

14. Case Study: Modular Facilities in pharmaceutical / Biotechnological Industry
15. Case Study: Technology and Equipment Providers
16. Case Study: Roadmap for the Adoption of Continuous Manufacturing Processes
17.  Market Forecast and Opportunity Analysis
18.  Conclusion
19.  Executive Insights
20.  Appendix 1: Tabulated Data
21.  Appendix 2: List of Companies and Organizations
To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/continuous-manufacturing/308.html
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
[email protected]is.com

You may also like


No comments yet... Be the first to leave a reply! Login here

0 Karma
1145 Posts

Made with by Mamby